Baculovirus as a vaccine vector

Lu, Hsin-Yu; Chen, Yi‐Hsuan; Liu, Hung-Jen

doi:10.4161/bioe.20679

Cited by 32 publications

(24 citation statements)

References 59 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this sense, many studies demonstrating the phenotypic and functional maturation of dendritic cells and macrophages as well as direct activation of B cells induced by AcNPV, resulting in antigen presentation and Th1 responses, have been reported [ 51 , 52 ]. Noteworthy, the acceptability for using baculovirus in humans has been recently increased with ongoing trials of gene therapy based on the use of such viruses as delivery system [ 53 ], which lays the foundation for safe and extended use of recombinant baculovirus systems in other areas such as vaccines [ 54 ].…”

Section: Discussionmentioning

confidence: 99%

Protection against Amoebic Liver Abscess in Hamster by Intramuscular Immunization with anAutographa californicaBaculovirus Driving the Expression of the Gal-Lectin LC3 Fragment

Meneses-Ruiz

Aguilar-Díaz

Bobes

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

In a previous study, we demonstrated that oral immunization using Autographa californica baculovirus driving the expression of the Gal-lectin LC3 fragment (AcNPV-LC3) of Entamoeba histolytica conferred protection against ALA development in hamsters. In this study, we determined the ability of AcNPV-LC3 to protect against ALA by the intramuscular route as well as the liver immune response associated with protection. Results showed that 55% of hamsters IM immunized with AcNPV-LC3 showed sterile protection against ALA, whereas other 20% showed reduction in the size and extent of abscesses, resulting in some protection in 75% of animals compared to the sham control group. Levels of protection showed a linear correlation with the development and intensity of specific antiamoeba cellular and humoral responses, evaluated in serum and spleen of hamsters, respectively. Evaluation of the Th1/Th2 cytokine patterns expressed in the liver of hamsters showed that sterile protection was associated with the production of high levels of IFNγ and IL-4. These results suggest that the baculovirus system is equally efficient by the intramuscular as well as the oral routes for ALA protection and that the Gal-lectin LC3 fragment is a highly protective antigen against hepatic amoebiasis through the local induction of IFNγ and IL-4.

show abstract

Section: Discussionmentioning

confidence: 99%

Protection against Amoebic Liver Abscess in Hamster by Intramuscular Immunization with anAutographa californicaBaculovirus Driving the Expression of the Gal-Lectin LC3 Fragment

Meneses-Ruiz

Aguilar-Díaz

Bobes

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Baculoviruses have a cloning capacity as large as 38 kb, allowing them to accommodate a single large insert or multiple genes encompassing regulatory elements [ 17 ]. These attributes have fueled interest in exploring baculoviruses as vectors for recombinant protein expression systems and gene therapy [ 18 – 20 ].…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1

Gwon¹,

Kim²,

Cho³

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

An outbreak of influenza H1N1 in 2009, representing the first influenza pandemic of the 21st century, was transmitted to over a million individuals and claimed 18,449 lives. The current status in many countries is to prepare influenza vaccine using cell-based or egg-based killed vaccine. However, traditional influenza vaccine platforms have several limitations. To overcome these limitations, many researchers have tried various approaches to develop alternative production platforms. One of the alternative approach, we reported the efficacy of influenza HA vaccination using a baculoviral DNA vaccine (AcHERV-HA). However, the immune response elicited by the AcHERV-HA vaccine, which only targets the HA antigen, was lower than that of the commercial killed vaccine. To overcome the limitations of this previous vaccine, we constructed a human endogenous retrovirus (HERV) envelope-coated, baculovirus-based, virus-like-particle (VLP)–forming DNA vaccine (termed AcHERV-VLP) against pandemic influenza A/California/04/2009 (pH1N1). BALB/c mice immunized with AcHERV-VLP (1×107 FFU AcHERV-VLP, i.m.) and compared with mice immunized with the killed vaccine or mice immunized with AcHERV-HA. As a result, AcHERV-VLP immunization produced a greater humoral immune response and exhibited neutralizing activity with an intrasubgroup H1 strain (PR8), elicited neutralizing antibody production, a high level of interferon-γ secretion in splenocytes, and diminished virus shedding in the lung after challenge with a lethal dose of influenza virus. In conclusion, VLP-forming baculovirus DNA vaccine could be a potential vaccine candidate capable of efficiently delivering DNA to the vaccinee and VLP forming DNA eliciting stronger immunogenicity than egg-based killed vaccines.

show abstract

“…This indicates a potent pro-inflammatory and Th1/Th2 mixed response with an impairment of humoral response involving B memory cells and immunoglobulins that could be responsible for the low protection in terms of worm recovery [ 44 ]. Another possible explanation of the differences in protection could be the post-translational modifications that occur in the different expression systems involving glycosylation and the fact that only one isoform was used [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems

et al. 2016

View full text Add to dashboard Cite

BackgroundSchistosomiasis is a water-borne disease afflicting over 261 million people in many areas of the developing countries with high morbidity and mortality. The control relies mainly on treatment with praziquantel. Fatty acid binding proteins (FABP) have demonstrated high levels of immune-protection against trematode infections. This study reports the immunoprotection induced by cross-reacting Fasciola hepatica FABP, native (nFh12) and recombinantly expressed using two different expression systems Escherichia coli (rFh15) and baculovirus (rFh15b) against Schistosoma mansoni infection.MethodsBALB/c mice were vaccinated with native nFh12 or recombinant rFh15 and rFh15 FABP from F. hepatica formulated in adjuvant adaptation (ADAD) system with natural or chemical synthesised immunomodulators (PAL and AA0029) and then challenged with 150 cercariae of S. mansoni. Parasite burden, hepatic lesions and antibody response were studied in vaccination trials. Furthermore differences between rFh15 and rFh15b immunological responses (cytokine production, splenocyte population and antibody levels) were studied.ResultsVaccination with nFh12 induced significant reductions in worm burden (83 %), eggs in tissues (82–92 %) and hepatic lesions (85 %) compared to infected controls using PAL. Vaccination with rFh15 showed lower total worm burden (56–64 %), eggs in the liver (21–61 %), eggs in the gut (30–77 %) and hepatic damage (67–69 %) using PAL and AA0029 as immunomodulators. In contrast, mice vaccinated with rFh15b showed only reductions in eggs trapped in the liver and intestine (53 and 60 %, respectively), and hepatic lesions (45 %). We observed a significant rise in TNFα, IL-6, IL-2, IL-4 and high antibody response (IgG, IgG1, IgG2a, IgM and IgE) in mice immunised with either rFh15 or rFh15b. Moreover, mice immunised with rFh15b showed an increase in IFNγ and a decrease in B220 cells compared to untreated mice, and less production of IgG1 and IgM than in mice immunised by rFh15.ConclusionsHigher level of protection is obtained by using Fasciola hepatica-derived FABP protein against Schistosoma mansoni infection. Native FABP is more effective than both recombinant systems. It could be due to post-translational modifications or FABP isoform or changes in the recombinant proteins.Electronic supplementary materialThe online version of this article (doi:10.1186/s13071-016-1500-y) contains supplementary material, which is available to authorized users.

show abstract

Baculovirus as a vaccine vector

Cited by 32 publications

References 59 publications

Protection against Amoebic Liver Abscess in Hamster by Intramuscular Immunization with anAutographa californicaBaculovirus Driving the Expression of the Gal-Lectin LC3 Fragment

Protection against Amoebic Liver Abscess in Hamster by Intramuscular Immunization with anAutographa californicaBaculovirus Driving the Expression of the Gal-Lectin LC3 Fragment

Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1

Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems

Contact Info

Product

Resources

About